Under the leadership of Warwick’s Department of Chemistry professor Peter Sadler, the researchers have designed a new line of treatment against cancer by using an organic-osmium compound. The
The approval is for the treatment of adult patients in whom the condition is inadequately controlled even after being subjected to high-dose inhaled corticosteroids and long-acting beta-agonists. The
The 5-ht6 antagonist failed to meet its primary efficacy endpoints in the phase 2b HEADWAY and pilot phase 2 Gait and Balance studies. In the HEADWAY trial, intepirdine
The board of Ablynx said that in the interests of all its stakeholders, it has come to a unanimous conclusion that the proposal also undervalues its future prospects
The deal is structured in three parts, with Celgene paying $1.1bn in cash upfront for Impact Biomedicines, which is currently engaged in the development of fedratinib for the treatment
The Japanese pharma firm said that the deal reinforces its commitment to patients with Inflammatory Bowel Disease (IBD), which currently has limited treatment options. The acquisition will also
Promacta can now be used in combination with standard immunosuppressive therapy to treat the rare blood disorder. SAA is a condition in which the bone marrow of the
The companies have announced a development strategy for M710, a proposed biosimilar to Eylea injection. Eylea is a vascular endothelial growth factor (VEGF) inhibitor developed to treat neovascular
The job cuts will affect employees engaged in the company's commercial and other functions. Allergan said in a US Securities and Exchange Commission filing that it will also terminate nearly 400 open
CNTX-4975 is a non-opioid therapy, which is designed to inject directly into the painful joint. The company has secured funding in the series D financing round led by New
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.